Management of patients with systematic mastocytosis: Review of M. D. Anderson Cancer Center experience

Bryan Hennessy, Francis Giles, Jorge Cortes, Susan O'Brien, Alessandra Ferrajoli, Gladys Ossa, Guillermo Garcia-Manero, Stefan Faderl, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalReview article

Abstract

Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed.

Original languageEnglish (US)
Pages (from-to)209-214
Number of pages6
JournalAmerican Journal of Hematology
Volume77
Issue number3
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Mastocytosis
Neoplasms
Cutaneous Mastocytosis
Myelodysplastic Syndromes
Cytarabine
Acute Myeloid Leukemia
Systemic Mastocytosis
Databases
Idarubicin
Induction Chemotherapy
Stem Cell Transplantation
Standard of Care
Interferon-alpha
Mast Cells

Keywords

  • Prognosis
  • Systemic mastocytosis
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Management of patients with systematic mastocytosis : Review of M. D. Anderson Cancer Center experience. / Hennessy, Bryan; Giles, Francis; Cortes, Jorge; O'Brien, Susan; Ferrajoli, Alessandra; Ossa, Gladys; Garcia-Manero, Guillermo; Faderl, Stefan; Kantarjian, Hagop; Verstovsek, Srdan.

In: American Journal of Hematology, Vol. 77, No. 3, 01.11.2004, p. 209-214.

Research output: Contribution to journalReview article

Hennessy, B, Giles, F, Cortes, J, O'Brien, S, Ferrajoli, A, Ossa, G, Garcia-Manero, G, Faderl, S, Kantarjian, H & Verstovsek, S 2004, 'Management of patients with systematic mastocytosis: Review of M. D. Anderson Cancer Center experience', American Journal of Hematology, vol. 77, no. 3, pp. 209-214. https://doi.org/10.1002/ajh.20211
Hennessy, Bryan ; Giles, Francis ; Cortes, Jorge ; O'Brien, Susan ; Ferrajoli, Alessandra ; Ossa, Gladys ; Garcia-Manero, Guillermo ; Faderl, Stefan ; Kantarjian, Hagop ; Verstovsek, Srdan. / Management of patients with systematic mastocytosis : Review of M. D. Anderson Cancer Center experience. In: American Journal of Hematology. 2004 ; Vol. 77, No. 3. pp. 209-214.
@article{fc4b794f6fd84b6ab5a213effe4e5894,
title = "Management of patients with systematic mastocytosis: Review of M. D. Anderson Cancer Center experience",
abstract = "Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed.",
keywords = "Prognosis, Systemic mastocytosis, Therapy",
author = "Bryan Hennessy and Francis Giles and Jorge Cortes and Susan O'Brien and Alessandra Ferrajoli and Gladys Ossa and Guillermo Garcia-Manero and Stefan Faderl and Hagop Kantarjian and Srdan Verstovsek",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/ajh.20211",
language = "English (US)",
volume = "77",
pages = "209--214",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Management of patients with systematic mastocytosis

T2 - Review of M. D. Anderson Cancer Center experience

AU - Hennessy, Bryan

AU - Giles, Francis

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Ferrajoli, Alessandra

AU - Ossa, Gladys

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed.

AB - Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed.

KW - Prognosis

KW - Systemic mastocytosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=7244257364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244257364&partnerID=8YFLogxK

U2 - 10.1002/ajh.20211

DO - 10.1002/ajh.20211

M3 - Review article

C2 - 15495258

AN - SCOPUS:7244257364

VL - 77

SP - 209

EP - 214

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -